Thermalin Company

Thermalin hopes to disrupt the $30B insulin/insulin delivery market with a disposable, postage-stamp-sized glucose management system enabled by our first-in-class stabilized, highly concentrated, and ultra-rapid acting insulin. This same new insulin molecule in "ordinary" (U-100) concentration will enable the factory-filling of reservoirs for existing insulin pumps. In addition to this lead program, Thermalin is developing partnerships on no-cold-chain basal and mix insulins and on glucose-responsive insulins.
Industry: PharmTech
Headquarters: Cleveland
Founded Date: 2010-01-01
Employees Number: 11-50
Investors Number: 6
Total Funding: $37,624,859
Estimated Revenue: $1M to $10M
Last Funding Type: Convertible Note

Visit Website
rick@thermalin.com
Register and Claim Ownership